CN1183951C - Medicine for treating non-gonococcal vaginitis and preparation method - Google Patents
Medicine for treating non-gonococcal vaginitis and preparation method Download PDFInfo
- Publication number
- CN1183951C CN1183951C CN 03113856 CN03113856A CN1183951C CN 1183951 C CN1183951 C CN 1183951C CN 03113856 CN03113856 CN 03113856 CN 03113856 A CN03113856 A CN 03113856A CN 1183951 C CN1183951 C CN 1183951C
- Authority
- CN
- China
- Prior art keywords
- medicine
- nongonococcal urethritis
- medicament
- weight portions
- ngu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims description 7
- 229940079593 drug Drugs 0.000 title description 15
- 206010046914 Vaginal infection Diseases 0.000 title 1
- 201000008100 Vaginitis Diseases 0.000 title 1
- 208000000143 urethritis Diseases 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- 239000002775 capsule Substances 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 241001523348 Picrasma Species 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- -1 drying Substances 0.000 claims description 2
- 208000004880 Polyuria Diseases 0.000 abstract description 7
- 230000035619 diuresis Effects 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 abstract description 6
- 230000027939 micturition Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 230000008602 contraction Effects 0.000 abstract description 4
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 230000036407 pain Effects 0.000 abstract description 3
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 210000003127 knee Anatomy 0.000 abstract description 2
- 210000002700 urine Anatomy 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 240000001972 Gardenia jasminoides Species 0.000 abstract 1
- 208000006083 Hypokinesia Diseases 0.000 abstract 1
- 235000002384 Malva verticillata Nutrition 0.000 abstract 1
- 240000003065 Malva verticillata Species 0.000 abstract 1
- 241000157511 Oldenlandia Species 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 206010003549 asthenia Diseases 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 210000003462 vein Anatomy 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 241000193996 Streptococcus pyogenes Species 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 241000606161 Chlamydia Species 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Abstract
The present invention discloses a medicament for curing nongonococcal urethritis (NGU), which is prepared from six types of traditional Chinese medicaments of gardenia, milk vetch, oldenlandia, ophiopogon roots, cluster mallow fruit and lignum quassiae used as raw materials. The present invention also discloses a method for preparing the medicament. The medicament for curing nongonococcal urethritis (NGU) has the efficiencies of clearing heat, promoting diuresis, benefiting Qi, nourishing Yin and inducing diuresis for curing strangurtia. The medicament for curing nongonococcal urethritis (NGU) is used for damp-heat in lower-JIAO of nongonococcal urethritis (NGU), a symptom of insufficiency of Qi and Yin, not serious hot urination of symptom shown, not conspicuous urine pain, incessant showering draining, repeated recurrence, lassitude loin and knees, fatigued spirit, hypodynamia, light texture of tongue and weak vein or weakness asthenia. A pharmacodynamics test shows that the medicine has the functions of resisting inflammation, resisting bacteria, enhancing immune function, inhibiting the contraction of a bladder and promoting urination and analgesic effect.
Description
Affiliated technical field
The present invention relates to a kind of medicine for the treatment of nongonococcal urethritis, being specifically related to a kind of is the Chinese patent medicine of feedstock production with the Chinese herbal medicine, the invention still further relates to the preparation method of this medicine.
Background technology
Nongonococcal urethritis is a kind of common, multiple urinary system illness, is a kind of sexually transmitted disease (STD) that sickness rate is only second to gonorrhea and condyloma acuminatum.Western medicine thinks that this disease is mainly caused by chlamydia and mycoplasma, infects by sexual intercourse, invades the urogenital organ.The male mainly shows as the scratchy and pain of urinating of urethra clinically, and minority has frequent micturition.Playing urethral orifice morning has a small amount of mucus secretions or only has the crust film to seal.Normal epididymitis, the prostatitis etc. of merging.The women is many to be that the center is diffused into other positions with the cervix uteri.Show as the urogenical infection symptom.Mucus cervicitis person performance has leucorrhoea grow in quantity, edema of cervix or erosion; Urethritis person shows as urethra scorching hot or frequent micturition, checks urethral orifice hyperemia, little red or normal, and the extruding urethra overflows with secretions, and many patients do not have any symptom.The medicine to mycoplasma and chlamydia cosensitize is selected in treatment for use, and as tetracycline, doxycycline, Roxithromycin, ofloxacin etc., but all class medicines all have stronger toxic action, and easily produce drug resistance, and curative effect and prognosis are not satisfactory.
Chinese medicine thinks that the center of stranguria etiology and pathogenesis is damp and hot, and its primary symptom promptly is tangible damp and hot card.For concrete patient, should control with card fully from the integral body of its body.No damp and hot be not stranguria then, grabbed toward this principal contradiction, just be familiar with the general character of this disease.In the actual therapeutic, the product of clear profit should run through in treatment all the time.
Summary of the invention
The object of the present invention is to provide a kind of is the medicine that can effectively treat nongonococcal urethritis that raw material is made with the Chinese herbal medicine, and this medicine has no side effect, taking convenience, and short treating period, evident in efficacy.
Another object of the present invention is to provide the preparation method of this medicine.
The medicine that is used for the treatment of nongonococcal urethritis provided by the invention is the medicament of being made by the raw material of following weight parts:
Fructus Gardeniae 18～30 Radixs Astragali 18～30 Herba Hedyotidis Diffusaes 15～26
Radix Ophiopogonis 15～26 Fructus Malvae, 15～26 Ramulus Et Folium Picrasmaes 8～20.
The above-mentioned medicine material that is used for the treatment of nongonococcal urethritis all meets " the regulation of relevant each kind of Chinese pharmacopoeia version in 2000.
The above-mentioned medicine that is used for the treatment of nongonococcal urethritis can be made said multiple dosage form on the pharmaceutics, as capsule, tablet, powder, oral liquid etc.
The above-mentioned preparation method that is used for the treatment of the medicine of nongonococcal urethritis may further comprise the steps:
(1) get Fructus Gardeniae 18～30 weight portions, Herba Hedyotidis Diffusae 15～26 weight portions, Ramulus Et Folium Picrasmae 8～20 weight portions with 60～80% alcohol heating reflux 2～4 times, each solvent multiple is that 6 times, return time are 1～3 hour; Merging filtrate, medicinal residues device are in addition preserved; Filtrate recycling ethanol, and to be concentrated into relative density be 1.20～1.35, the alcohol extraction clear paste;
(2) get the Radix Astragali 18～30 weight portions, Fructus Malvae 15～26 weight portions, Radix Ophiopogonis 15～26 weight portion with decoct with water 2～4 times after above-mentioned medicinal residues mix, each amount of water is that 8 times, decocting time are 1～3 hour; Merging filtrate is concentrated into relative density 1.10～1.15, adds ethanol and makes and contain the alcohol amount and reach 60～80%, cold preservation 24～96 hours is filtered, and reclaims ethanol and is concentrated into relative density 1.32～1.35, with above-mentioned alcohol extraction clear paste mixing, drying is ground into fine powder, granulate, drying, granulate adds an amount of dry starch mixing, encapsulated, make capsule.
The present invention has clearing away heat-damp and promoting diuresis, supplementing QI and nourishing YIN, the effect of inducing diuresis for treating stranguria syndrome.Be used for hold concurrently deficiency of both vital energy and Yin card of nongonococcal urethritis damp-heat in lower-JIAO, disease is seen hot urination not very, and excessive pain is outstanding, drenches drop endlessly, outbreak repeatedly, and soreness of the waist and knees, spiritlessness and weakness, pale tongue, deficient and weak pulse or void are carefully unable.Medicine of the present invention is used for that the nongonococcal urethritis effect is rapid, and effect is remarkable, has no adverse reaction.
The invention will be further described below by embodiment and toxicology and pharmacology experimental result.
Embodiment 1
Get Fructus Gardeniae 260g, Herba Hedyotidis Diffusae 235g, Ramulus Et Folium Picrasmae 150g, with 60% alcohol heating reflux 2 times, the solvent multiple is 8 times, and return time is 2h; Merging filtrate, medicinal residues device are in addition preserved.Filtrate recycling ethanol also is concentrated into the clear paste that relative density is 1.35 (60 ℃), and is standby.Other get Radix Astragali 240g, Fructus Malvae 230g, Radix Ophiopogonis 200g with decoct with water 2 times after above-mentioned medicinal residues mix, amount of water is 8 times, decocting time is 2h; Merging filtrate is concentrated into relative density 1.10 (60 ℃), adds ethanol and makes and contain the alcohol amount and reach 60%, cold preservation 50h filters, and reclaims ethanol, and be concentrated into relative density 1.32 (60 ℃), with above-mentioned alcohol extraction clear paste mixing, in 65 ℃ of dryings, be ground into fine powder, granulate drying, granulate, add the abundant mix homogeneously of an amount of dry starch, encapsulated, make capsule of the present invention.
Embodiment 2
Get Fructus Gardeniae 220g, Herba Hedyotidis Diffusae 230g, Ramulus Et Folium Picrasmae 180g, with 70% alcohol heating reflux 3 times, each solvent multiple is that 6 times, return time are 1h; Merging filtrate, medicinal residues device are in addition preserved.Filtrate recycling ethanol also is concentrated into the clear paste that relative density is 1.32 (60 ℃), and is standby.Other get Radix Astragali 220g, Fructus Malvae 250g, Radix Ophiopogonis 220g with decoct with water 3 times after above-mentioned medicinal residues mix, each amount of water is that 10 times, decocting time are 1h; Merging filtrate is concentrated into relative density 1.15 (60 ℃), adds ethanol and makes and contain the alcohol amount and reach 70%, cold preservation 60h filters, and reclaims ethanol, medicinal liquid is concentrated into relative density 1.33 (60 ℃), with alcohol extraction clear paste mixing, in 65 ℃ of dryings, be ground into fine powder, granulate drying, granulate, add an amount of dry starch mixing, encapsulated, make capsule of the present invention.
The present invention is to provide a kind of natural drug for the treatment of nongonococcal urethritis, for proving its therapeutic effect and safety, the inventor uses the capsule for preparing by the method that provides in the foregoing description 1 to carry out toxicity and pharmacodynamics test, and result of study is as follows:
One, acute toxicity test
Studied the acute toxicity of capsule of the present invention to mice.The result shows, after the capsule mouse stomach of the present invention administration, does not find obvious acute toxicity, and mice maximum dosage-feeding on the one is 98.56g crude drug/kg, and 622 times of consumptions every day are equivalent to be grown up.
Two, long term toxicity test
The capsular clinical course of treatment according to the present invention according to the specification requirement of new Chinese medicine toxicologic study, has been studied 3 month long term toxicities of capsule of the present invention to rat.The result shows, with three dosage of capsule of the present invention (4.75,9.5,19g crude drug/kg, 30 times, 60 times, 120 times of consumption are equivalent to respectively to be grown up) give rat continuous irrigation stomach 3 months, general situation, hematology, blood biochemical, routine urinalysis, electrocardiogram, system's dissection, organ coefficient and histopathology to rat all do not have obvious influence, do not find toxic reaction, convalescent period does not also have the retardance toxic reaction, and it is 19g crude drug/kg/ day that rat non-toxic reaction dosage is provided.The result shows that capsule of the present invention is not seen obvious accumulative toxicity to rat, estimates to be safe under the clinical dosage condition.
Three, pharmacodynamic study
Capsule of the present invention is a compound Chinese medicinal preparation, has the effect of clearing away heat-damp and promoting diuresis, supplementing QI and nourishing YIN, clinically is used for the urinary system infection treatment of chronic phase.According to the present invention capsular effect with cure mainly, according to the principle and the method for " study of tcm new drug guide ", to capsule of the present invention carried out antiinflammatory, antibiotic, Immune Effects, influence, diuresis and analgesia etc. to bladder contraction are cured mainly relevant Pharmacodynamic test of active extract research with function.Result of study shows, capsule of the present invention by 3.22,6.44,12.88g crude drug/kg is to the mouse stomach administration, reaction of chmice acute exudative inflammation and mouse writhing that suppressing acetic acid stimulates react; By 2.3,4.6,9.2g crude drug/kg is to the rat oral gavage administration, suppresses reaction of rat chronic proliferative inflammation and rat in the body bladder contraction; By 1.24,2.48,4.96g crude drug/kg is to the rabbit gastric infusion, obviously increases rabbit urine amount.Immunological testing is the result show, capsule of the present invention by 3.22,6.44,12.88g crude drug/kg is to the mouse stomach administration, and the growth of mouse immune organ is not had obvious influence; Improve the cytophagous phagocytic function of mice, the enhancing body non-specific immunity; Promote the generation and the secretion of mice specific antibody, strengthen the specific humoral immunity function of mice; Promote the mouse spleen lymphocyte breeder reaction, strengthen the specific cellular immunity function of mice.Antibacterial tests result shows, capsule body of the present invention is outer to be had than obvious suppression and deactivation removing from office the blue negative cocci gonococcus of blue positive coccus staphylococcus aureus, staphylococcus epidermidis, streptococcus pyogenes and leather, do not have obvious inhibitory action to removing from office blue negative cocci streptococcus faecalis of blue negative bacillus colon bacillus, Pseudomonas aeruginosa, Salmonella enteritidis, acinetobacter calcoaceticus, Bacillus proteus and leather and fungus saccharomyces albicans, the pH and the bacterial load that change culture fluid do not influence the antibacterial action of capsule of the present invention to streptococcus pyogenes, staphylococcus epidermidis; Gastric infusion; in the body streptococcus pyogenes and staphylococcus epidermidis infecting mouse all there is protective effect; ED50 to the streptococcus pyogenes infecting mouse is 64.15g crude drug/kg; 95% credible 48.41～77.24g crude drug/kg that is limited to; ED50 to epidermis staphy lococcus infection mice is 32.51g crude drug/kg, 95% credible 24.17～43.73g crude drug/kg that is limited to.Presentation of results, capsule of the present invention have antiinflammatory, antibiotic, raise immunity, inhibition bladder contraction and diuresis, analgesic activity.
Claims (3)
1, a kind of medicine for the treatment of nongonococcal urethritis is characterized in that it is the medicament of being made by the raw material of following weight parts:
Fructus Gardeniae 18～30 Radixs Astragali 18～30 Herba Hedyotidis Diffusaes 15～26
Radix Ophiopogonis 15～26 Fructus Malvae, 15～26 Ramulus Et Folium Picrasmaes 8～20.
2, the medicine of treatment nongonococcal urethritis according to claim 1 is characterized in that described medicament is a capsule.
3, the preparation method of the medicine of the described treatment nongonococcal urethritis of claim 2 may further comprise the steps:
(1) get Fructus Gardeniae 18～30 weight portions, Herba Hedyotidis Diffusae 15～26 weight portions, Ramulus Et Folium Picrasmae 8～20 weight portions with 60～80% alcohol heating reflux 2～4 times, each solvent multiple is that 6 times, return time are 1～3 hour; Merging filtrate, medicinal residues device are in addition preserved; Filtrate recycling ethanol, and to be concentrated into relative density be 1.20～1.35, the alcohol extraction clear paste;
(2) get the Radix Astragali 18～30 weight portions, Fructus Malvae 15～26 weight portions, Radix Ophiopogonis 15～26 weight portion with decoct with water 2～4 times after above-mentioned medicinal residues mix, each amount of water is that 8 times, decocting time are 1～3 hour; Merging filtrate is concentrated into relative density 1.10～1.15, adds ethanol and makes and contain the alcohol amount and reach 60～80%, cold preservation 24～96 hours is filtered, and reclaims ethanol and is concentrated into relative density 1.32～1.35, with above-mentioned alcohol extraction clear paste mixing, drying is ground into fine powder, granulate, drying, granulate adds an amount of dry starch mixing, encapsulated, make capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03113856 CN1183951C (en) | 2003-03-05 | 2003-03-05 | Medicine for treating non-gonococcal vaginitis and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03113856 CN1183951C (en) | 2003-03-05 | 2003-03-05 | Medicine for treating non-gonococcal vaginitis and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1438016A CN1438016A (en) | 2003-08-27 |
| CN1183951C true CN1183951C (en) | 2005-01-12 |
Family
ID=27674050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03113856 Expired - Lifetime CN1183951C (en) | 2003-03-05 | 2003-03-05 | Medicine for treating non-gonococcal vaginitis and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1183951C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2279736A1 (en) * | 2004-03-12 | 2011-02-02 | Life Science Investments Ltd. | Microbicidal and antiparasitic compositions comprising quassinoids or quassionid-containing plant extracts |
| CN103076403B (en) * | 2012-10-07 | 2014-10-22 | 贵州远程制药有限责任公司 | Inspection method for capsule for treating lower urinary tract infection |
| CN102973791A (en) * | 2012-12-20 | 2013-03-20 | 贵州远程制药有限责任公司 | Drug for treating simplex lower urinary tract infection and preparation method thereof |
-
2003
- 2003-03-05 CN CN 03113856 patent/CN1183951C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1438016A (en) | 2003-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101869626B (en) | Chinese medicinal compound preparation private care liquid, and preparation and application thereof | |
| CN102552769B (en) | Medicine for treating vaginitis and preparation method thereof | |
| CN103860958A (en) | Traditional Chinese medicinal composition for treating acne | |
| CN103007124A (en) | Chinese medicine preparation for treating gynecologic inflammation | |
| CN101433655B (en) | Chinese medicinal composition for treating colpitis | |
| CN101391065B (en) | Compound momordica seed pepper soup for treating urgent chronic pelvic inflammatory disease | |
| CN102631641A (en) | Clysis liquid for treating pelvic inflammation | |
| CN1183951C (en) | Medicine for treating non-gonococcal vaginitis and preparation method | |
| CN101234184B (en) | Orally-administered Chinese medicine composition for treating radiation proctitis | |
| CN100546618C (en) | The psoriatic Chinese medicine preparation of a kind of treatment | |
| CN105477490A (en) | Pharmaceutical preparation for treating gynecological vulvae itching and application of pharmaceutical preparation | |
| CN102283991B (en) | Medicament for treating acute urinary system infection and preparation method thereof | |
| CN103751532A (en) | Traditional Chinese medicine composition for treating gynecological inflammation and preparation method thereof | |
| CN101912513B (en) | Traditional Chinese medicinal preparation for treating eczema | |
| CN101879224A (en) | Oral administration medicament for treating psoriasis | |
| CN1241596C (en) | Oral Chinese traditional medicine preparation for treating cystitis | |
| CN102935188A (en) | Traditional Chinese medicine composition for treating candidiasis | |
| CN103520620B (en) | A kind of Chinese medicine preparation and preparation method for the treatment of due to weakness of spleen and stomach chronic gastritis | |
| CN102973916A (en) | Chinese medicine formula for treating chronic enteritis and preparation method of Chinese medicine formulae | |
| CN102973696A (en) | Traditional Chinese medicine composition for treating chronic enteritis and preparation method of traditional Chinese medicine composition | |
| CN103372187A (en) | Medicine for treating urticaria | |
| CN101757369A (en) | Medicine composition for treating acute goutry arthritis and preparation process thereof | |
| CN102188643A (en) | Medicament for treating damp-heat blockage syndrome and its preparation method | |
| CN105287838A (en) | Traditional Chinese medicine formula used for treatment skin dry-dampness pruritus | |
| CN104587078A (en) | Traditional Chinese medicine preparation for treating viral pharyngitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: GUIZHOU YUANCHENG PHARMACEUTICAL CO. Free format text: FORMER OWNER: WU MEICHUN Effective date: 20040514 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20040514 Address after: 550018 national hi tech Industrial Development Zone, Guizhou, Guiyang Applicant after: GUIZHOU REMOTE PHARMACEUTICAL CO.,LTD. Address before: 510610 Guangdong city of Guangzhou province forest and Road No. 150, Room 802 on the eighth floor of Tianyu Garden Plaza Accord Applicant before: Wu Meichun |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 550018 No. 5 Gaoxin North Road, Wudang District, Guiyang City, Guizhou Province Patentee after: GUIZHOU REMOTE PHARMACEUTICAL Co.,Ltd. Address before: 550018 national hi tech Industrial Development Zone, Guizhou, Guiyang Patentee before: GUIZHOU REMOTE PHARMACEUTICAL Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050112 |